Athira Pharma (ATHA) to Release Earnings on Wednesday

Athira Pharma (NASDAQ:ATHA) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Athira Pharma to post earnings of ($0.20) per share for the quarter.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). On average, analysts expect Athira Pharma to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Athira Pharma Stock Down 2.5%

ATHA stock opened at $0.27 on Monday. Athira Pharma has a 52-week low of $0.22 and a 52-week high of $3.67. The stock’s fifty day simple moving average is $0.28 and its 200-day simple moving average is $0.46. The stock has a market capitalization of $10.62 million, a price-to-earnings ratio of -0.10 and a beta of 3.04.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.